Inhaled corticosteroids for stable chronic obstructive pulmonary disease

Predictive factors for exacerbation and reexacerbation in chronic obstructive pulmonary disease: an extension of the Cox model to analyze data from the Swiss COPD cohort

“…In accordance with the findings of Green et al our analysis confirms the high prevalence of comorbidities, in contrast to their findings we found even higher rates of cardiac comorbidities [33]. The risk factors associated with exacerbation and re-exacerbation are largely in accordance with the literature [18,36,37], however the association of prescription of short-acting bronchodilators, inhaled or systemic corticosteroids was perhaps surprising, as some large trials have shown significant decrease in exacerbation risk with the use of inhaled steroids [38,39]. However, a recent study of Magnussen et al showed a similar risk of moderate or severe exacerbations for patients discontinuing inhaled glucocorticoids compared to patients who continued inhaled glucocorticoid treatment [40].…”

Predictive factors for exacerbation and reexacerbation in chronic obstructive pulmonary disease: an extension of the Cox model to analyze data from the Swiss COPD cohort

“…In accordance with the findings of Green et al our analysis confirms the high prevalence of comorbidities, in contrast to their findings we found even higher rates of cardiac comorbidities [33]. The risk factors associated with exacerbation and re-exacerbation are largely in accordance with the literature [18,36,37], however the association of prescription of short-acting bronchodilators, inhaled or systemic corticosteroids was perhaps surprising, as some large trials have shown significant decrease in exacerbation risk with the use of inhaled steroids [38,39]. However, a recent study of Magnussen et al showed a similar risk of moderate or severe exacerbations for patients discontinuing inhaled glucocorticoids compared to patients who continued inhaled glucocorticoid treatment [40].…”

Predictive factors for exacerbation and re-exacerbation in chronic obstructive pulmonary disease: an extension of the Cox model to analyze data from the Swiss COPD cohort

“…The risk factors associated with exacerbation and re-exacerbation are largely in accordance with the literature [18, 36, 37], however the association of prescription of short-acting bronchodilators, inhaled or systemic corticosteroids was perhaps surprising, as some large trials have shown significant decrease in exacerbation risk with the use of inhaled steroids [38, 39]. However, a recent study of Magnussen et al showed a similar risk of moderate or severe exacerbations for patients discontinuing inhaled glucocorticoids compared to patients who continued inhaled glucocorticoid treatment [40].…”

Prescribing of inhaled corticosteroids-containing and non-inhaled corticosteroids therapy in patients with chronic obstructive pulmonary disease at a Malaysian tertiary care center

“…No prescribing of ICS monotherapy was observed after 2019. This aligns with the treatment recommendation in the GOLD guidelines, which outline that ICS therapy only had minor beneficial effects on symptoms and exacerbations, and the benefits are outweighed by the longterm side effects, which include pneumonia (Vogelmeier et al, 2017;Yang et al, 2012).…”

Predictive factors for exacerbation and reexacerbation in chronic obstructive pulmonary disease: an extension of the Cox model to analyze data from the Swiss COPD cohort

“…In accordance with the findings of Green et al our analysis confirms the high prevalence of comorbidities, in contrast to their findings we found even higher rates of cardiac comorbidities [33]. The risk factors associated with exacerbation and re-exacerbation are largely in accordance with the literature [18,36,37], however the association of prescription of short-acting bronchodilators, inhaled or systemic corticosteroids was perhaps surprising, as some large trials have shown significant decrease in exacerbation risk with the use of inhaled steroids [38,39]. However, a recent study of Magnussen et al showed a similar risk of moderate or severe exacerbations for patients discontinuing inhaled glucocorticoids compared to patients who continued inhaled glucocorticoid treatment [40].…”

Predictive factors for exacerbation and re-exacerbation in chronic obstructive pulmonary disease: an extension of the Cox model to analyze data from the Swiss COPD cohort

“…The risk factors associated with exacerbation and re-exacerbation are largely in accordance with the literature [18, 36, 37], however the association of prescription of short-acting bronchodilators, inhaled or systemic corticosteroids was perhaps surprising, as some large trials have shown significant decrease in exacerbation risk with the use of inhaled steroids [38, 39]. However, a recent study of Magnussen et al showed a similar risk of moderate or severe exacerbations for patients discontinuing inhaled glucocorticoids compared to patients who continued inhaled glucocorticoid treatment [40].…”

Prescribing of inhaled corticosteroids-containing and non-inhaled corticosteroids therapy in patients with chronic obstructive pulmonary disease at a Malaysian tertiary care center

“…No prescribing of ICS monotherapy was observed after 2019. This aligns with the treatment recommendation in the GOLD guidelines, which outline that ICS therapy only had minor beneficial effects on symptoms and exacerbations, and the benefits are outweighed by the longterm side effects, which include pneumonia (Vogelmeier et al, 2017;Yang et al, 2012).…”

Predictive factors for exacerbation and reexacerbation in chronic obstructive pulmonary disease: an extension of the Cox model to analyze data from the Swiss COPD cohort

“…In accordance with the findings of Green et al our analysis confirms the high prevalence of comorbidities, in contrast to their findings we found even higher rates of cardiac comorbidities [33]. The risk factors associated with exacerbation and re-exacerbation are largely in accordance with the literature [18,36,37], however the association of prescription of short-acting bronchodilators, inhaled or systemic corticosteroids was perhaps surprising, as some large trials have shown significant decrease in exacerbation risk with the use of inhaled steroids [38,39]. However, a recent study of Magnussen et al showed a similar risk of moderate or severe exacerbations for patients discontinuing inhaled glucocorticoids compared to patients who continued inhaled glucocorticoid treatment [40].…”

Predictive factors for exacerbation and re-exacerbation in chronic obstructive pulmonary disease: an extension of the Cox model to analyze data from the Swiss COPD cohort

“…The risk factors associated with exacerbation and re-exacerbation are largely in accordance with the literature [18, 36, 37], however the association of prescription of short-acting bronchodilators, inhaled or systemic corticosteroids was perhaps surprising, as some large trials have shown significant decrease in exacerbation risk with the use of inhaled steroids [38, 39]. However, a recent study of Magnussen et al showed a similar risk of moderate or severe exacerbations for patients discontinuing inhaled glucocorticoids compared to patients who continued inhaled glucocorticoid treatment [40].…”

Prescribing of inhaled corticosteroids-containing and non-inhaled corticosteroids therapy in patients with chronic obstructive pulmonary disease at a Malaysian tertiary care center

“…No prescribing of ICS monotherapy was observed after 2019. This aligns with the treatment recommendation in the GOLD guidelines, which outline that ICS therapy only had minor beneficial effects on symptoms and exacerbations, and the benefits are outweighed by the longterm side effects, which include pneumonia (Vogelmeier et al, 2017;Yang et al, 2012).…”